In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae
- PMID: 11796366
- PMCID: PMC127069
- DOI: 10.1128/AAC.46.2.517-518.2002
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae
Abstract
The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
References
-
- Barry, A. I., and P. C. Fuchs. 1997. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J. Chemother. 9:9-16. - PubMed
-
- Centers for Disease Control and Prevention. 1998. 1998 Guidelines for the treatment of sexually transmitted diseases. Morb. Mortal. Wkly. Rep. 47(RR-1):53-60. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
